

[Ondansetron](#)

Essential medicine status

Section:

[2. Medicines for pain and palliative care](#) [2.3. Medicines for other common symptoms in palliative care](#)

ATC codes: [A04AA01](#)

EMLc

Indication

Palliative care ICD11 code: [QC7A](#)

INN

Ondansetron

Medicine type

Chemical agent

List type

Core

Formulations

Parenteral > General injections > IV: 2 mg per mL in 2 mL ampoule (as hydrochloride dihydrate) ; 2 mg per mL in 4 mL ampoule (as hydrochloride dihydrate)

Oral > Liquid: 4 mg per 5 mL (as hydrochloride dihydrate)

Oral > Solid: 4 mg (as hydrochloride dihydrate) ; 8 mg (as hydrochloride dihydrate)

EML status history

First added in 2011 ([TRS 965](#))

Changed in 2019 ([TRS 1021](#))

Changed in 2021 ([TRS 1035](#))

Changed in 2025 ([TRS 1064](#))

Sex

All

Age

Also recommended for children

Therapeutic alternatives

[dolasetron](#) (ATC codes: [A04AA04](#))

[granisetron](#) (ATC codes: [A04AA02](#))

[palonosetron](#) (ATC codes: [A04AA05](#))

[tropisetron](#) (ATC codes: [A04AA03](#))

Patent information

Patents have expired in most jurisdictions

Read more [about patents](#).

Wikipedia

[Ondansetron](#)

DrugBank

[Ondansetron](#)

Summary of evidence and Expert Committee recommendations

Following the review of the age-appropriateness of formulations on the EMLc, the Expert Committee recommended: - the addition of ondansetron injection 2 mg/mL in 4 mL ampoule to the EML and EMLc; - to modify the formulation descriptions to consistently describe the available dosage forms.